UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000046657
Receipt number R000052610
Scientific Title efficacy and safety of Isochronal late activation mapping guided SVC isolation
Date of disclosure of the study information 2022/01/20
Last modified on 2023/09/27 05:48:51

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

efficacy and safety of Isochronal late activation mapping guided SVC isolation

Acronym

efficacy and safety of Isochronal late activation mapping guided SVC isolation

Scientific Title

efficacy and safety of Isochronal late activation mapping guided SVC isolation

Scientific Title:Acronym

efficacy and safety of Isochronal late activation mapping guided SVC isolation

Region

Japan


Condition

Condition

Atrial fibrillation

Classification by specialty

Cardiology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

A conventional method of the superior vena cava (SVC) isolation, which ablate circumferentially the right atrium (RA) and SVC junction line identified by angiography has reported to be associated with several complications such as phrenic nerve or sinus node injury. Thus, we often have cases of difficulty in SVC isolation by the conventional method.
Isochronal late activation map (ILAM) is a novel functional substrate mapping technique to identify the critical isthmus of reentrant ventricular arrhythmias.
We hypothesized that the ILAM could efficiently identify the SVC sleeve and conduction block line, which would contribute to minimize the procedure time, fluoroscopy time, radiofrequency delivery, and complications. The purpose of this study is to reveal the clinical utility and feasibility of ILAM in SVC isolation compared to the conventional method.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

The completion rate of SVC isolation

Key secondary outcomes

Procedure time (time from the start of SVC isolation to the completion of isolation), fluoroscopy time, number of RF deliveries, total RF energy, complications (phrenic nerve injury, sinus node injury, SVC stenosis, cardiac tamponade)


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Maneuver

Interventions/Control_1

The electroanatomical maps of SVC and RA during sinus rhythm are constructed by high-density mapping catheter (AdvisorTM HD Grid Mapping Catheter, Abbott, St. Paul, MN) and EnSite X system (Abbott, St. Paul, MN). The location of SVC sleeve and RA-SVC conduction block line are identified by using the ILAM. Radiofrequency applications are delivered along the line connecting the ends of conduction block lines. The procedure success of SVC isolation is defined as a bidirectional block between the SVC and the RA.

Interventions/Control_2

SVC angiography is performed to identify anatomical RA-SVC junction. RF applications are delivered along circumferential line beyond the RA-SVC junction. The procedure success of SVC isolation is defined as a bidirectional block between the SVC and the RA.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who undergo catheter ablation for atrial fibrillation and meet the following conditions.
・ 2nd session
・ Persistent atrial fibrillation
・ Suspected SVC origin PAC inducing AF

Key exclusion criteria

・ Under 20 years old
・ Patients undergoing SVC isolation at the time of initial treatment
・ Patients with a pacemaker or bradyarrhythmia
・ Patients with initial treatment of catheter ablation for paroxysmal atrial fibrillation with no evidence of atrial fibrillation induced by PAC originating from SVC
・ Patients with poor SVC potential and no SVC sleeve length
・ Others who are deemed inappropriate by the investigator or the research coordinator

Target sample size

200


Research contact person

Name of lead principal investigator

1st name Yukiko
Middle name
Last name Nakano

Organization

Hiroshima University Graduate School of Biomedical and Health Sciences

Division name

Department of Cardiovascular Medicine

Zip code

734-8551

Address

1-2-3 Kasumi, Minami-ku, Hiroshima City, Hiroshima Prefecture

TEL

082-257-5540

Email

nakanoy@hiroshima-u.ac.jp


Public contact

Name of contact person

1st name Naoto
Middle name
Last name Oguri

Organization

Hiroshima University Graduate School of Biomedical and Health Sciences

Division name

Department of Cardiovascular Medicine

Zip code

734-8551

Address

1-2-3 Kasumi, Minami-ku, Hiroshima City, Hiroshima Prefecture

TEL

082-257-5540

Homepage URL


Email

d216209@hiroshima-u.ac.jp


Sponsor or person

Institute

Hiroshima University

Institute

Department

Personal name



Funding Source

Organization

Hiroshima University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Center for integrated medical research

Address

1-2-3 Kasumi, Minami-ku, Hiroshima City, Hiroshima Prefecture

Tel

082-257-5596

Email

hugcp@hiroshima-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 01 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2021 Year 11 Month 12 Day

Date of IRB

2021 Year 12 Month 16 Day

Anticipated trial start date

2022 Year 01 Month 20 Day

Last follow-up date

2024 Year 12 Month 31 Day

Date of closure to data entry

2024 Year 12 Month 31 Day

Date trial data considered complete

2024 Year 12 Month 31 Day

Date analysis concluded

2025 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2022 Year 01 Month 17 Day

Last modified on

2023 Year 09 Month 27 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000052610


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name